Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic, Jv; Ivey, A; Vannucchi, Alessandro Maria; Lippert, E; Oppliger Leibundgut, E; Cassinat, B; Pallisgaard, N; Maroc, N; Hermouet, S; Nickless, G; Guglielmelli, Paola; Van Der Reijden Ba,; Jansen, Jh; Alpermann, T; Schnittger, S; Bench, A; Tobal, K; Wilkins, B; Cuthill, K; Mclornan, D; Yeoman, K; Akiki, S; Bryon, J; Jeffries, S; Jones, A; Percy, Mj; Schwemmers, S; Gruender, A; Kelley, Tw; Reading, S; Pancrazzi, Alessandro; Mcmullin, Mf; Pahl, Hl; Cross, Nc; Harrison, Cn; Prchal, Jt; Chomienne, C; Kiladjian, Jj; Barbui, T; Grimwade, D.

doi:10.1038/leu.2013.219

studio europeo per la standardizzazione della metodlogia molecolare pe rle mutazioni di jak2

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study / Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, et al.. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 27:(2013), pp. 2032-2039. [10.1038/leu.2013.219]